natgillin/translations-raw huggingface dataset:
- thoughts about threatening the life of others, - mania (excessive or unreasonable enthusiasm), - pericarditis (inflammation of the lining of the heart), pericardial effusion [a fluid collection that develops between the pericardium (the lining of the heart) and the heart itself.
misli kako ogroziti življenja drugih, manija (pretirano in nerazumno navdušenje), perikarditis (vnetje srčne zaklopke), perikardno iztekanje [tekočina se nabira med perikardom
Most cases of anaemia, neutropenia, and thrombocytopenia were mild (WHO grades 1 or 2).
Večina primerov anemije, nevtropenije in trombocitopenije je bila blagih (1. ali 2. stopnje po SZO).
Consideration should be given to replacing zidovudine in a combination anti-retroviral treatment (ART) regimen if this is already established.
Premislite, ali bi bilo treba pri zdravljenju z uveljavljeno kombinirano protivirusno shemo (ART) morda zamenjati zidovudin.
Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and in height percentiles were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3rd percentile in 70 % of the patients).
Hujšanje in zastoj rasti sta bila zelo pogosta med zdravljenjem (ob koncu zdravljenja je znašalo povprečno zmanjšanje telesne mase in višine glede na osnovno vrednost 15 percentilov oziroma 8 percentilov) in tudi njihova hitrost rasti je bila zmanjšana (upočasnila se je za do 3 percentile pri 70 % bolnikov).
In a clinical trial with 107 children and adolescent patients (3 to 17 years of age) treated with combination therapy of peginterferon alfa-2b and ribavirin, dose modifications were required in 25 % of patients, most commonly for anaemia, neutropenia and weight loss.
V kliničnem preskušanju pri 107 otrocih in mladostnikih (starih od 3 do 17 let), zdravljenih s kombinirano terapijo s peginterferonom alfa-2b in ribavirinom, je bila potrebna prilagoditev odmerka pri 25 % bolnikov, najpogosteje zaradi anemije, nevtropenije ali hujšanja.
Renal function: Single-dose ribavirin pharmacokinetics were altered (increased AUCtf and Cmax) in patients with renal dysfunction compared with control subjects (creatinine clearance > 90 ml/minute).
Delovanje ledvic: Pri bolnikih z motnjami delovanja ledvic je bila farmakokinetika ribavirina po enkratnem odmerku spremenjena (povečanje AUCtf in Cmax) glede na kontrolno skupino (očistek kreatinina > 90 ml/minuto).
• tablet core: microcrystalline cellulose, crospovidone, povidone K25, silica colloidal, magnesium stearate
• jedro tablete: mikrokristalna celuloza, krospovidon, povidon K 25, koloidni silicijev dioksid,
Ribavirin BioPartners must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
Zdravljenja z zdravilom Ribavirin BioPartners ne smete uvesti, dokler ne dobite negativnega izvida testa nosečnosti tik pred začetkom zdravljenja;
HCV infected patients having a co-occurring substance use disorder (alcohol, cannabis, etc) are at an increased risk of developing psychiatric disorders or exacerbation of already existing psychiatric disorders when treated with alpha interferon.
Bolniki, okuženi s HCV, ki sočasno uživajo tudi opojne substance (alkohol, marihuano, itd.), imajo med zdravljenjem z interferonom alfa povečano tveganje za nov pojav psihiatričnih motenj ali za poslabšanje že obstoječih psihiatričnih motenj.
Ribavirin BioPartners must be used in combination with interferon alfa-2b (3 million international units [MIU] three times a week).
Zdravilo Ribavirin BioPartners morate uporabljati v kombinaciji z interferonom alfa-2b (3 milijone mednarodnih enot (mio i.e.) trikrat na teden).
Like all medicines, Ribavirin BioPartners used in combination with an alpha interferon product can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Ribavirin BioPartners v kombinaciji z interferonom alfa neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
In
vsi
Ribavirin: Ribavirin is embryotoxic or teratogenic, or both, at doses well below the recommended human dose in all animal species in which studies have been conducted.
Ribavirin: Ribavirin je bil pri vseh živalskih vrstah, pri katerih so bile opravljene študije, embriotoksičen, teratogen ali oboje v odmerkih, precej manjših od priporočenega odmerka za človeka.
Antacid: The bioavailability of ribavirin 600 mg was decreased by co-administration with an antacid containing magnesium aluminium and simethicone; AUCtf decreased 14 %.
Antacid: Biološka uporabnost ribavirina v odmerku 600 mg se je zmanjšala pri sočasni uporabi antacida z magnezijem, aluminijem in simetikonom.
These studies suggest that a carcinogenic potential
Te študije kažejo, da je kancerogenost ribavirina za človeka malo verjetna.
- Genotoxicity: Ribavirin induces genotoxicity (see section 5.3).
− Genotoksičnost: Ribavirin povzroča genotoksične učinke (glejte poglavje 5.3).
Adding treatment with alfa interferons alone or in combination with ribavirin may increase the risk in this patient subset.
Dodatek terapije z interferoni alfa, samimi ali v kombinaciji z ribavirinom, lahko poveča tveganje pri tej podskupini bolnikov.
You should consult your doctor immediately if any of the following side effects occur during treatment with Ribavirin BioPartners and interferon alfa-2b:
Nemudoma se posvetujte s svojim zdravnikom, če se pojavi kateri od naslednjih neželenih učinkov med zdravljenjem z zdravilom Ribavirin BioPartners v kombinaciji z interferonom alfa-2b:
Adding treatment with an alpha interferon alone or in combination with ribavirin may increase the risk in this patient subset.
Dodatno zdravljenje s samimi alfa interferoni ali v kombinaciji z ribavirinom lahko namreč poveča tveganje pri tej podskupini bolnikov.
Alanine aminotransferase (ALT)
Alaninaminotransferaz
In clinical studies performed in this population ribavirin and interferon alfa-2b were used in doses of 15 mg/kg/day and 3 million international units (MIU)/m2 three times a week respectively (Table 2).
V kliničnih študijah izvajanih s to populacijo sta se ribavirin in interferon alfa-2b uporabljala v odmerku 15 mg/kg/dan in 3 milijone mednarodnih enot (mio i.e.)/m2 trikrat na dan (preglednica 2).
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 30 IU/ml), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
V ta klinična preskušanja so vključili bolnike s kroničnim hepatitisom C, potrjenim s pozitivnim izvidom testa polimerazne verižne reakcije (PCR) na HCVRNK (> 30 i.e./ml), izvid jetrne biopsije pa je bil v skladu s histološko diagnozo kroničnega hepatitisa brez drugih vzrokov za kronični hepatitis, poleg tega pa so imeli bolniki tudi nenormalne serumske vrednosti ALT.
The dose of Ribavirin BioPartners is based on patient body weight (Table 1).
Odmerek zdravila Ribavirin BioPartners se določi na podlagi bolnikove telesne mase (preglednica 1).
There is no evidence from toxicity studies that ribavirin induces liver enzymes.
Raziskave toksičnosti niso pokazale nobenih znakov, da bi ribavirin morda induciral jetrne encime.
All but one of the paediatric subjects remained sustained virologic responders during long-term follow-up after completion of treatment with interferon alfa-2b plus ribavirin.
Pri vseh pediatričnih bolnikih razen enega se je ohranil trajni virološki odziv med dolgoročnim spremljanjem po zaključku zdravljenja z interferonom alfa-2b in ribavirinom.
Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with non-pegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa-2b (with or without ribavirin), respectively.
Dolgoročni podatki o učinkovitosti - odrasli bolniki V dve veliki, dolgoročni študiji spremljanja bolnikov po zdravljenju v prejšnjih študijah so vključili skupaj 1.071 bolnikov po končanem zdravljenju z nepegiliranim interferonom alfa-2b (z ali brez ribavirina) ter 567 bolnikov po končanem zdravljenju s pegiliranim interferonom alfa-2b (z ali brez ribavirina).
If you are a woman who is breast-feeding, you must not take Ribavirin BioPartners.
Če ste ženska, ki doji, ne smete uporabljati zdravila Ribavirin BioPartners.
Study 1 (see section 5.1), decrease in absolute neutrophil count levels below 500 cells/mm3 was observed in 4 % (8/194) of patients and decrease in platelets below 50,000/mm3 was observed in 4 %
V študiji 1 (glejte poglavje 5.1) so opazili zmanjšanje absolutnega števila nevtrofilcev pod 500 celic/mm3 pri 4 % (8/194) bolnikov in zmanjšanje števila trombocitov pod 50.000/mm3 pri 4 % (8/194) bolnikov, ki so prejemali ribavirin v kombinaciji s peginterferonom alfa-2b.
Existence of, or history of severe psychiatric condition, particularly severe depression, suicidal
− Obstoječa huda duševna bolezen ali huda duševna bolezen v anamnezi, še posebej huda depresija, samomorilne misli ali poskus samomora.
The dose of Ribavirin BioPartners is based on patient body weight.
Odmerek zdravila Ribavirin BioPartners se določi na podlagi bolnikove telesne mase.
Reminder: Please read the “Do not use” section of the Package Leaflet for interferon alfa-2b before you begin combination treatment with Ribavirin BioPartners.
Opozorilo: Prosim, prebrati morate tudi poglavje „Ne uporabljajte“ v navodilih za uporabo za interferon alfa-2b, preden začnete kombinirajo zdravljenje z zdravilom Ribavirin BioPartners.
This myelotoxicity was reversible within 4 to 6 weeks upon withdrawal of HCV antiviral therapy and concomitant azathioprine and did not recur upon reintroduction of either treatment alone (see section 4.5).
Mielotoksičnost je bila reverzibilna v 4 do 6 tednih po prekinitvi protivirusne terapije za HCV in sočasnega azatioprina in se po ponovni uvedbi enega od obeh zdravljenj ni ponovila (glejte
WHAT RIBAVIRIN BIOPARTNERS IS AND WHAT IT IS USED FOR Ribavirin BioPartners contains the active ingredient ribavirin.
KAJ JE ZDRAVILO RIBAVIRIN BIOPARTNERS IN ZA KAJ GA UPORABLJAMO Zdravilo Ribavirin BioPartners vsebuje učinkovino ribavirin.
P1.5/R Ribavirin (800 mg) + peginterferon alfa-2b (1.5 micrograms/kg) P0.5/R Ribavirin (1,000/1,200 mg) + peginterferon alfa-2b (1.5 to 0.5 microgram/kg) I/R Ribavirin (1,000/1,200 mg) + interferon alfa-2b (3 MIU)
P1,5/R Ribavirin (800 mg) + peginterferon alfa-2b (1,5 mikrogramov/kg) P0,5/R Ribavirin (1.000/1.200 mg) + peginterferon alfa-2b (1,5 do 0,5 mikrogramov/kg) I/R Ribavirin (1.000/1.200 mg) + interferon alfa-2b (3 mio i.e.)
Laboratory tests: Standard haematologic tests and blood chemistries (complete blood count [CBC] and differential, platelet count, electrolytes, serum creatinine, liver function tests, uric acid) must be conducted in all patients prior to initiating therapy.
Laboratorijske preiskave: Pred pričetkom zdravljenja morate pri vseh bolnikih opraviti standardne hematološke in biokemične preiskave krvi (celotno krvno sliko in diferencialno krvno sliko, število trombocitov, določanje vrednosti elektrolitov in serumskega kreatinina, jetrne funkcijske teste, določanje vrednosti sečne kisline).
Dose modifications were required in 30 % of patients, most
Prilagoditev odmerka je bila potrebna pri 30 % bolnikov, najpogosteje zaradi anemije in nevtropenije.
Your doctor has determined the correct dose of Ribavirin BioPartners based on how much you or the child
Zdravnik vam je določil ustrezen odmerek zdravila Ribavirin BioPartners na podlagi vaše telesne mase ali telesne mase otroka, za katerega skrbite.
- Lactation.
− Navodilo shranite.
In clinical trials with ribavirin used in combination with peginterferon alfa-2b or interferon alfa-2b, the maximum overdose reported was a total dose of 10 g of ribavirin (50 x 200 mg) and 39 MIU of interferon alfa-2b (13 subcutaneous injections of 3 MIU each) taken in one day by a patient in an attempt at suicide.
V kliničnih preskušanjih ribavirina v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b so poročali o prevelikem odmerku 10 g ribavirina (50 x 200 mg) in 39 mio i.e. interferona alfa-2b (13 subkutanih injekcij po 3 mio i.e. vsaka), ki ga je v enem dnevu vzel bolnik v poskusu samomora.
Please read the “Possible side effects” section of the Package Leaflet for interferon alfa-2b.
Preberite tudi poglavje „Možni neželeni učinki“ v navodilu za uporabo interferona alfa-2b.
Severe adverse reactions were reported in 7 % (8/107) of all subjects and included injection site pain (1 %), pain in extremity (1 %), headache (1 %), neutropenia (1 %), and pyrexia (4 %).
Hudi neželeni učinki so bili prijavljeni pri 7 % (8/107) vseh preizkušancev in mednje so sodili bolečina na mestu injiciranja (1 %), bolečina v udih (1 %), glavobol (1 %), nevtropenija (1 %) in zvišana telesna temperatura (4 %).
In HCV/HIV co-infected patients receiving HAART, the following other side effects have occurred with the combination of ribavirin and peginterferon alfa-2b (not listed above in adults side effects):
Pri bolnikih, ki so sočasno okuženi z virusoma HCV in HIV in prejemajo HAART, so se pojavili tudi naslednji dodatni neželeni učinki pri kombinaciji ribavirina in peginterferona alfa-2b ((ki niso našteti zgoraj pri neželenih učinkih za odrasle):
- With zidovudine or stavudine, it is not certain if Ribavirin BioPartners will change the way these medicines work.
Ni znano, ali lahko zdravilo Ribavirin BioPartners spremeni delovanje teh zdravil.
If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Ribavirin and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as
Če psihiatrični simptomi ne prenehajo ali se celo poslabšajo, ali če ugotovite, da ima bolnik samomorilne misli, je priporočljivo, da prekinete zdravljenje z ribavirinom in peginterferonom alfa-2b ali interferonom alfa-2b in bolnika spremljate, po potrebi tudi s psihiatrično intervencijo.
Prior to initiation of interferon alfa-2b therapy, TSH levels must be evaluated and any thyroid abnormality detected at that time must be treated with conventional therapy.
Pred uvedbo terapije z interferonom alfa-2b morate ovrednotiti vrednost TSH in morebitne motnje v delovanju ščitnice, ki jih ugotovite v tem času, zdraviti z ustaljeno terapijo.
Ribavirin BioPartners 200 mg film-coated tablets ribavirin
Ribavirin BioPartners 200 mg filmsko obložene tablete ribavirin
Patients with existence of or history of severe psychiatric conditions: If treatment with Ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b is judged necessary in adult patients with existence or history of severe psychiatric conditions, this should only be initiated after having ensured appropriate individualised diagnostic and therapeutic management of the psychiatric condition.
Bolniki s hudimi psihiatričnimi motnjami v sedanji ali pretekli anamnezi: Če ocenite, da je potrebno zdravljenje z ribavirinom v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b pri odraslih bolnikih z obstoječimi hudimi psihiatričnimi motnjami ali s hudimi psihijatričnimi motnjami v anamnezi, ga smete uvesti šele potem, ko ste zagotovili ustrezno individualno diagnostično in terapevtsko obravnavo psihiatrične motnje.
Bacterial infection (including sepsis), fungal infection, influenza, respiratory tract infection, bronchitis, herpes simplex, sinusitis, otitis media, rhinitis, urinary tract infection
bakterijska okužba (vključno s sepso),glivična okužba, gripa, okužba zgornjih dihal, bronhitis, herpes simpleks, sinusitis, otitis media, rinitis, okužbe sečil okužba na mestu injiciranja, okužba spodnjih dihal
d interferon alfa-2b (3 MIU TIW)
interferon alfa-2b (3 mio i.e., TNT)
Reported adverse reactions listed in Table 5 are based on experience from the two multicentre children and adolescents clinical trials using ribavirin with interferon alfa-2b or peginterferon alfa-2b.
Prijavljeni neželeni učinki, ki so navedeni v Preglednici 5, temeljijo na izkušnjah iz dveh multicentričnih kliničnih preskušanj za otroke in mladostnike, kjer so uporabljali ribavirin z interferonom alfa-2b ali peginterferonom alfa-2b.
Limited safety data (N = 25) are available in co-infected patients with CD4+ cell counts < 200/µl (see section 4.4).
Za sočasno okužene bolnike s številom celic CD4+ < 200/µl so na voljo le omejeni podatki o varnosti zdravila (N = 25) (glejte poglavje 4.4).
Some data suggest that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/ribavirin therapy.
Nekateri podatki kažejo, da obstaja pri tistih bolnikih, ki so sočasno okuženi z virusoma HIV in HCV ter prejemajo ART z abakavirjem, tveganje za manjšo stopnjo odziva na zdravljenje s pegiliranim interferonom in ribavirinom.
Ribavirin BioPartners film-coated tablets for oral use - dose based on body weight
Zdravilo Ribavirin BioPartners filmsko obložene tablete za peroralno uporabo - odmerek na podlagi
A reduction in haemoglobin concentrations by > 4 g/dl was observed in 30 % of patients treated with ribavirin and peginterferon alfa-2b and 37 % of patients treated with ribavirin and interferon alfa-2b.
Zmanjšanje koncentracije hemoglobina za > 4 g/dl so opazili pri 30 % bolnikov, ki so prejemali ribavirin in peginterferon alfa-2b, ter pri 37 % bolnikov, ki so prejemali ribavirin in interferon alfa-2b.
However, this does not preclude the occurrence of hepatic events in patients with cirrhosis (including hepatocarcinoma).
To pa ne izključuje pojava jetrnih dogodkov pri bolnikih s cirozo, vključno s
Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received ribavirin 15 mg/kg per day plus interferon alfa-2b 3 MIU/m2 3 times a week for 1 year followed by 6 months follow-up after treatment.
Kombinirana terapija ribavirina in interferona alfa-2b Otroci in mladostniki, stari od 3 do 16 let in s kompenziranim kroničnim hepatitisom C in merljivimi količinami HCV RNA (kar je ocenil osrednji laboratorij z uporabo raziskovalnega testa RT-PCR), so bili vključeni v dve multicentrični preskušanji in so ribavirin prejemali v odmerku 15 mg/kg na dan skupaj z interferonom alfa-2b v odmerku 3 mio i.e./m2 trikrat na teden v času enega leta, čemur je sledilo 6-mesečno spremljanje po zdravljenju.
For females of childbearing potential: Female patients must have a routine pregnancy test performed monthly during treatment and for four months thereafter.
Ženske v rodni dobi: Bolnice morajo rutinsko opravljati nosečnostni test vsak mesec med zdravljenjem in še štiri mesece po njem.
Ribavirin has been shown to produce high inter- and intra-subject pharmacokinetic variability following single oral doses (intrasubject variability of approximately 30 % for both AUC and Cmax), which may be due to extensive first pass metabolism and transfer within and beyond the blood
Za ribavirin so dokazali veliko inter- in intraindividualno farmakokinetično variabilnost po enkratnem peroralnem odmerku (variabilnost pri posamezniku je bila približno 30 % tako za AUC kot za Cmax).
• are a male and your female partner is of childbearing age (see section “Pregnancy and
• moški in je vaša partnerica v rodni dobi (glejte poglavje „Nosečnost in dojenje“).
Children and adolescents are particularly prone to develop depression when being treated with ribavirin and interferon alpha.
Otroci in mladostniki: Otrocih so še bolj nagnjeni k depresiji kadar so zdravljeni z zdravilom Ribavirin BioPartners in interferonom alfa.
Ribavirin plus interferon: When used in combination with peginterferon alfa-2b or interferon alfa-2b, ribavirin did not cause any effects not previously seen with either active substance alone.
Ribavirin + interferon: Ribavirin v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b ni povzročil nobenih učinkov, ki ne bi že bili opisani v zvezi s samostojno uporabo obeh učinkovin.
There were some cases of more severe neutropenia in patients treated with ribavirin in combination with peginterferon alfa-2b (WHO grade 3: 39 of 186 [21 %]; and WHO grade 4: 13 of 186 [7 %]); WHO grade 3 leukopenia was also reported in 7 % of this treatment group.
Bilo je tudi nekaj primerov hujše nevtropenije (3. stopnje po SZO: 39 od 186 [21 %] in 4. stopnje po SZO: 13 od 186 [7 %]) med bolniki, zdravljenimi z zdravilom Ribavirin BioPartners v kombinaciji s peginterferonom alfa-2b; pri 7 % bolnikov iz te terapevtske skupine so poročali tudi o levkopeniji
During treatment with Ribavirin in combination therapy with an alpha interferon, dental and gum disorders, which may lead to loss of teeth, have been reported.
Med zdravljenjem z ribavirinom in enim od interferonov alfa so poročali o zobnih boleznih in boleznih dlesni, ki lahko vodijo do izgube zob.
Ribavirin BioPartners is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b.
Zdravilo Ribavirin BioPartners je indicirano za zdravljenje kroničnih okužb z virusom hepatitisa C (HCV) pri odraslih, otrocih starejših od 3 let in mladostnikih in ga morate uporabljati izključno v kombinaciji z interferonom alfa-2b.
Patients co-infected with HCV/HIV: Patients taking nucleoside reverse transcriptase inhibitor (NRTI) treatment in association with ribavirin and interferon alfa-2b may be at increased risk of mitochondrial toxicity, lactic acidosis and hepatic decompensation (see section 4.4).
Bolniki, ki imajo sočasno okužbo s HCV/HIV: Bolniki, ki prejemajo terapijo z zaviralci nukleozidne reverzne transkriptaze (nucleoside reverse transcriptase inhibitor - NRTI) skupaj z ribavirinom in interferonom alfa-2b, imajo lahko povečano tveganje za nastanek toksičnost za mitohondrije, laktacidoze in jetrne dekompenzacije (glejte poglavje 4.4).
In particular, decrease in mean height percentile at year 1 of long term follow-up was most prominent in prepubertal age children (see section 4.4).
Znižanje srednje vrednosti telesne mase opazovanih bolnikov (50. percentila) v enem letu po začetku spremljanja je bilo najbolj izrazito pri otrocih pred puberteto (glej poglavje 4.4).
The use of ribavirin is contraindicated in patients with severe hepatic impairment or decompensated cirrhosis (see section 4.3).
Uporaba ribavirina je kontraindicirana pri bolnikih s hudo jetrno okvaro ali dekompenzirano cirozo (glejte
In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when ribavirin is
Pri bolnikih, pozitivnih na HIV, ki se zdravijo po shemi NRTI, mora zdravnik skrbno spremljati pokazatelje toksičnost za mitohondrije in laktacidoze pri sočasnem zdravljenju z ribavirinom, še posebej:
The safety and efficacy of this combination have been established only using ribavirin together with peginterferon alfa-2b or interferon alfa-2b solution for injection.
Varnost in učinkovitost te kombinacije je bila ugotovljena le pri uporabi ribavirina skupaj z raztopino za injiciranje peginterferona alfa-2b ali interferona alfa-2b.
The pharmacokinetics of ribavirin and interferon alfa-2b (dose-normalized) are similar in adults and
Farmakokinetika zdravila Ribavirin BioPartners in interferona alfa-2b (z normaliziranim odmerkom) je podobna pri odraslih in otrocih ali mladostnikih.
Female partners of male patients must have a routine pregnancy test performed monthly during treatment and for seven months thereafter (see
Partnerke bolnikov morajo rutinsko opravljati nosečnostni test vsak mesec med zdravljenjem in še sedem mesecev po njem (glejte poglavje 4.6).
Ribavirin BioPartners film-coated tablets in combination with interferon alfa-2b:
Filmsko obložene tablete zdravila Ribavirin BioPartners v kombinaciji z interferonom alfa-2b: